Key information relevant to the recruitment process for the
overall study, such as dates of the recruitment period and locations

From September 28th, 2007 to October 16th, 2008, 164 patients were enrolled in the study by 16 centres with a main activity in thyroid cancer in 7 European countries. Among these 164 patients, 145 patients were randomised to receive vandetanib 300 mg once daily oral dose or placebo.

Pre-Assignment Details

Significant events and approaches for the overall study
following participant enrollment, but prior to group assignment

The main reason for non-randomisation was non-respect of eligibility criteria

Explanation of how the number of participants for analysis was determined.
Includes whether analysis was per protocol, intention to treat, or another method.
Also provides relevant details such as imputation technique, as appropriate.